Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.
New research suggests that cats are the only common household pet associated with higher rates of anxiety and behavioral issues in young children, raising questions about pet ownership decisions for families with toddlers.
Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.
Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.
Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.
Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.
Vistagen announced topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, showing favorable safety and tolerability profiles along with efficacy signals across primary and secondary endpoints in both repeat and single dose administrations.
Researchers demonstrate fingertip sensors can identify physical patterns linked to stress, anxiety and depression, while major wearable companies including Whoop, Oura, and Apple expand into healthcare applications. Amae Health partners with Google Health to integrate Fitbit and voice biomarkers for precision psychiatry.
